# Exploring the Protective Effect of Gastrodia elata Extract on D-Galactose-Induced Liver Injury in Mice Based on the PI3K/Akt Signaling Pathway

**Authors:** Liu Han, Hongyu Zhai, Xiangyu Ma, He Li, Qiaosen Ren, Jiating Liu, Zhe Zhang, Xintong Li, Qiuyue Zhang, Xin Sun

PMC · DOI: 10.3390/cimb48010006 · Current Issues in Molecular Biology · 2025-12-20

## TL;DR

This study shows that Gastrodia elata extract protects mouse livers from D-galactose-induced damage by reducing inflammation and oxidative stress through the PI3K/Akt pathway.

## Contribution

The novel contribution is identifying the PI3K/Akt pathway as a key mechanism through which Gastrodia elata extract exerts hepatoprotective effects in a D-galactose-induced mouse model.

## Key findings

- Gastrodia elata extract reduced D-galactose-induced liver injury in mice by lowering oxidative stress and inflammation.
- The extract activated the PI3K/Akt signaling pathway, which is linked to reduced apoptosis and improved liver health.
- UPLC-MS/MS identified bioactive compounds in Gastrodia elata, including amino acids, fatty acids, and terpenoids.

## Abstract

In this research, we sought to methodically examine the protective effects of Gastrodia elata extract (GEE) on liver damage induced by D-galactose (D-gal) in mice and clarify the underlying mechanisms. The chemical composition of GEE was characterized using Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry (UPLC-MS/MS), while network pharmacology analysis was employed to predict potential molecular targets and signaling pathways. A mouse model of liver injury was established through daily intraperitoneal injection of D-gal over a 42-day period, during which the hepatoprotective efficacy of GEE was evaluated. Biochemical, histopathological, and molecular analyses were subsequently performed. UPLC-MS/MS identified ingredients such as amino acids, aromatic compounds, fatty acids, and terpenoids in GEE. A network pharmacology analysis enabled the identification of 272 common targets linked to GEE and liver damage, demonstrating notable enrichment within the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway. In vivo experiments demonstrated that GEE effectively alleviated D-gal-induced body weight loss and elevated liver index values, alleviated hepatic histological damage, and reduced serum levels of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Alkaline Phosphatase (ALP). Furthermore, GEE enhanced the activities of the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT), decreased malondialdehyde (MDA) levels, and downregulated the mRNA expression of the pro-inflammatory cytokines Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β), and Tumor Necrosis Factor-alpha (TNF-α). Western blot analysis confirmed that GEE activated the PI3K/Akt pathway, as evidenced by increased ratios of phosphorylated Phosphatidylinositol 3-kinase/Phosphatidylinositol 3-kinase (p-PI3K/PI3K) and phosphorylated AKT/Protein Kinase B (p-AKT/AKT); restored the B-cell lymphoma 2-associated X protein/B-cell lymphoma-2 (Bax/Bcl-2) balance; and reduced cyclin-dependent kinase inhibitor 1 (p21) expression. The results suggest that GEE protects against D-gal-induced liver damage by reducing oxidative stress, inhibiting inflammatory responses, and modulating apoptosis through the activation of the PI3K/Akt signaling pathway, providing support for its potential use in hepatoprotection.

## Linked entities

- **Proteins:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), Akt (Akt kinase), BAX (BCL2 associated X, apoptosis regulator), BCL2 (BCL2 apoptosis regulator), CDKN1A (cyclin dependent kinase inhibitor 1A), SOD1 (superoxide dismutase 1), CAT (catalase), so (sine oculis), IL6 (interleukin 6), IL1B (interleukin 1 beta), TNF (tumor necrosis factor)
- **Chemicals:** D-galactose (PubChem CID 206), fatty acids (PubChem CID 264), ALT (PubChem CID 10219674), ALP (PubChem CID 1392)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}
- **Diseases:** hepatic histological damage (MESH:D056486), weight loss (MESH:D015431), inflammatory (MESH:D007249), Liver Injury (MESH:D017093)
- **Chemicals:** terpenoids (MESH:D013729), MDA (MESH:D008315), amino acids (MESH:D000596), fatty acids (MESH:D005227), D-Galactose (MESH:D005690), compounds (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12840178/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12840178/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12840178/full.md

---
Source: https://tomesphere.com/paper/PMC12840178